← Back to Clinical Trials
Recruiting NCT06509230

NCT06509230 Prediction of Significant Liver Fibrosis

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT06509230
Status Recruiting
Phase
Sponsor Huang Haijun
Condition Liver Fibrosis
Study Type OBSERVATIONAL
Enrollment 700 participants
Start Date 2024-07-20
Primary Completion 2024-12-31

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age 60 Years
Study Type OBSERVATIONAL

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.

This trial targets 700 participants in total. It began in 2024-07-20 with a primary completion date of 2024-12-31.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

The deep learning method based on convolutional neural network (CNN) was used to extract the relevant features of liver fibrosis classification from the multi-modal information of digital pathological sections, clinical parameters and biomarkers of a large number of existing cases of liver puncture, and the U-Net architecture of CNN was used to segment and extract the features of clinical medical images.

Eligibility Criteria

Inclusion Criteria: 1. Age of 18-60 years old 2. The diagnosis of chronic hepatitis B is in line with the diagnostic criteria of China's 2019 Chronic Hepatitis B Prevention and Treatment Guidelines, and the diagnosis of non-alcoholic fatty liver is in line with the Asian Pacific Hepatology Association guidelines 3. Imaging showed no liver cancer Exclusion Criteria: 1. There are contraindications for liver biopsy 2. Liver pathology did not meet the criteria

Contact & Investigator

Central Contact

Haijun Huang

✉ huanghaijun0826@163.com

📞 13758186635

Frequently Asked Questions

Who can join the NCT06509230 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, up to 60 Years, studying Liver Fibrosis. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT06509230 currently recruiting?

Yes, NCT06509230 is actively recruiting participants. Contact the research team at huanghaijun0826@163.com for enrollment information.

Where is the NCT06509230 trial being conducted?

This trial is being conducted at Hangzhou, China.

Who is sponsoring the NCT06509230 clinical trial?

NCT06509230 is sponsored by Huang Haijun. The trial plans to enroll 700 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: September 2026  ·  Data Methodology